



FELICIA CRAICK

CONTACT INFO

1201 Third Avenue, Suite 3400
Seattle, WA 98101
(206) 623-1900
fcraick@kellerrohrback.com

PRACTICE EMPHASIS

- Class Action and Consumer Litigation
- Governments and Municipalities

EDUCATION

Northeastern University

B.S., *summa cum laude*,
Criminal Justice

Harvard Law School

J.D., *cum laude*

Felicia delves deep into the issues at hand to get concrete results for her clients.

As a partner in Keller Rohrback's nationally recognized Complex Litigation Group, Felicia is able to combine her interest in people with her drive to hold bad actors responsible for wrongdoing.

Drawn to cases that matter to people's lives, Felicia focuses on complex and multidistrict litigation. In the *In re: Social Media Adolescent Addiction/ Personal Injury Product Liability Litigation* MDL and *California's Judicial Council Coordination Proceedings ("JCCP") re Social Media Cases*, she represents school districts in litigation against the social media companies for their contributions to the youth mental health crisis. In the fight against the youth vaping epidemic, Felicia played a major role representing government entities in the *In re JUUL Labs, Inc., Marketing, Sales Practices, and Products Liability Litigation*, including participating in the San Francisco Unified School district trial against Altria Group, Inc. (the parent company of Philip Morris USA). In 2022, global settlements were reached with JUUL. In 2023, after the plaintiff rested its case, Altria agreed to a \$235 million settlement. As a result of the work in the *In re JUUL* case, Felicia was one of several attorneys on the JUUL team to receive the prestigious "California Lawyer Attorney of the Year" (CLAY) Award for the JUUL litigation from the Consumer Attorneys of California.

Felicia has also represented consumers in cases where the business practices of drug manufacturers, pharmacy benefit managers, and other entities have driven up the costs of pharmaceuticals to the detriment of consumers, such as in the *In re EpiPen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation*, which successfully reached a \$345 million settlement with Pfizer in 2021 and a \$264 million settlement with Mylan in 2022. As a result of the work in the *In re EpiPen* case, she and her team were honored by the American Antitrust Institute, winning an Outstanding Antitrust Litigation Achievement in Private Practice Award in 2022.

Prior to joining Keller Rohrback as an attorney, Felicia received her J.D., cum laude, from Harvard Law School, where she served as an Executive Article Editor of the Harvard Law & Policy Review. Felicia gained practical legal experience as a clinical student attorney, representing low-income survivors of domestic violence in family court and prosecuting criminal cases in state court, and as a summer associate at Keller Rohrback. Driven by the work of complex litigation and the firm's justice-oriented community, Felicia returned to Keller Rohrback at the conclusion of her clerkship with Washington State Supreme Court Chief Justice Mary Fairhurst.

Outside of work, Felicia enjoys hiking, watching soccer and gymnastics, and reading fantasy novels.

BAR & COURT ADMISSIONS

2019, Washington
2019, Western District of Washington
2022, U.S. Court of Appeals for the Ninth Circuit
2023, Supreme Court of the United States

PROFESSIONAL & CIVIC INVOLVEMENT

Washington Women Lawyers, *Member*
Washington State Bar Litigation Section, *Member*
Washington State Bar Criminal Law Section, *Member*

HONORS & AWARDS

Member of team selected as *Consumer Attorneys of the Year*, Consumer Attorneys of California, 2024
Selected to Rising Stars list in *Super Lawyers - Washington*, 2021-2024
Recognized by Puget Sound business Journal as a "Next Gen in Law" recipient, September 2023
American Antitrust Institute - Antitrust Enforcement Award Honoree, in the category of "Outstanding Antitrust Litigation Achievement in Private Law Practice" for work in *In re EpiPen Marketing, Sales Practices, and Antitrust Litigation*, 2022